TCD601 (Siplizumab)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TCD601 (Siplizumab), covering 2025-08-14 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients [Phase 1]